Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
54 /100
HIGH RISK
Score updated Oct 13, 2026

NTLA — Intellia Therapeutics, Inc. Dilution Risk Tracker

Track NTLA dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track NTLA — Get alerts when the score changes →

As of October 13, 2026, Intellia Therapeutics, Inc. (NTLA) has a DilutionWatch DilutionScore of 54/100, rated HIGH dilution risk. Intellia Therapeutics, Inc. has a market capitalization of $1.76B, 140.13M shares outstanding, 310 institutional holders tracked. Stored dilution-related fields include ATM program capacity of $180.00M.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
65
📊 Float Risk
17
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

⛅
Watch
Minor dilution signals detected
model est. 16%
💰 Capital Raise model 33%
• Under 12 months cash (11mo)
• Active ATM program with $180M remaining capacity
🔔 Track NTLA — Get forecast alerts →

Market Data

Market Cap$1.76B
Shares Outstanding140.13M
Float134.16M
Cash$437.76M
Debt$80.49M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore54/100DilutionWatch score record
Shares Outstanding140.13MVerified float table or market cache
Public Float134.16MVerified float table or market cache
Market Cap$1.76BMarket data cache
Cash Runway10.6 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM Capacity$180.00MSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 5.

Recent SEC source mix: 4 2, 424B5 2, 8-K 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 23.8% shares (2026Q1 vs prior)
310 institutional holders · 137.81M shares
#1 ARK Investment Management LLC 14.51M shares
#2 BlackRock, Inc. 12.16M shares
#3 MORGAN STANLEY 10.43M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest45.11M
Days to Cover9.5
% of Float33.6%
FINRA data as of Sep 30, 2026

Recent SEC Activity

8-K 8K EVENT 2026-04-30
424B5 ATM 2026-04-29
424B5 ATM 2026-04-27
4 INSIDER TRANSACTION 2026-03-03
4 INSIDER TRANSACTION 2026-03-03
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual NTLA Dilution Snapshot

Intellia Therapeutics, Inc. (NTLA) has a DilutionScore of 54/100, rated High dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

NTLA's DilutionScore has held steady at 54/100 (High risk) for 89 consecutive days across the tracked period.

Period Score Risk Level Duration
Jul 16 – Oct 13, 202654/100HIGH89 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

NTLA shares outstanding have increased 18.3% from 118.13M (Mar 2026) to 139.72M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 12, 2026139.72M134.16M▲ 18.27%
May 10, 2026118.93M113.43M▲ 0.47%
May 09, 2026118.93M112.90M▲ 0.85%
Apr 01, 2026118.13M111.94M▲ 0.02%
Mar 13, 2026118.13M111.92M▼ 0.36%
Mar 05, 2026118.13M112.32M▲ 0.10%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track NTLA Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment NTLA files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking NTLA — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for NTLA
NTLA FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.